Endocrine Abstracts

Chronic kidney disease (CKD) occurs in approximately 48% of our patient cohort living with type 2 diabetes (T2DM), and leads to an increase in cardiovascular morbidity, mortality and healthcare costs. Several risk management strategies can be used to improve outcomes in people with diabetes and CKD, primarily through the use of renin-angiotensin system (RAS) inhibitors, and selective glucose-lowering medications, namely sodium-glucose cotransport 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonist (GLP1RA), in T2DM. We conducted an audit to capture our adherence to screening and risk management of CKD in patients attending our service with T2DM, as per the American Diabetes Association Standards of Care. A retrospective review of all patients with T2DM who attended our outpatient clinic over a 2-week period in November 2024 was performed. In total, 49 patients were included (57% male, mean age 65.78 (+/- 11.55) years, Mean duration of diabetes 13.88 (+/- 9.05 ) years, mean HbA1C 63 (+/- 10) mmol/l/mol. Screening for CKD was performed in 47/96% of patients by measurement of both urine albumin-to-creatinine ratio (UACR) and eGFR at least once in the last year. A RAS inhibitor was prescribed for 92% of suitable patients. Only 76% and 57% of appropriate patients were on an SGTL2i and GLP1RA, respectively. 88% of patients who met criterial for referral to nephrology were referred. Screening for CKD in T2DM is optimal in our practice. There is a valuable opportunity to optimise the use of SGLT2is and GLP-1 receptor agonists with reno-protective benefits in this patient cohort.